Tonix Pharmaceuticals is a leading biopharmaceutical company based in New York, NY. With a strong focus on central nervous system disorders, immunology, infectious diseases, and rare diseases, Tonix is dedicated to developing innovative therapies to address unmet medical needs. Their robust pipeline includes a range of programs in various stages of development, from preclinical to preparing for FDA approval, encompassing both small molecules and biologics. Tonix's team of passionate professionals collaborates with government institutions, academic research organizations, and other biotech companies to advance their proprietary product candidates and bring them to market, aiming to provide relief and improve the lives of millions of patients worldwide. With a mission to heal the sufferings of millions, Tonix Pharmaceuticals is committed to finding cures for chronic disorders of the central nervous system, such as pain, neurological conditions, psychiatric disorders, and addiction. They also focus on developing therapeutics to prevent organ transplant rejection, manage autoimmune conditions, and enhance responses to immunotherapy in certain cancers. In addition, Tonix's infectious disease portfolio targets pathogenic infections, including the ongoing COVID-19 pandemic, utilizing vaccines, antivirals, and a Long COVID therapeutic. Furthermore, Tonix is dedicated to improving patient care for rare diseases, characterized by complex symptoms and affecting fewer than 200,000 people in the US. Through their integrated clinical development engine, Tonix maximizes the potential of their innovative programs, advancing them through clinical trials with the ultimate goal of FDA approval and making a positive impact on the lives of those in need.
Generated from the website